AGP Picks
View all

Exploring the health and wellness news of Barbados

Provided by AGP

Health Press Barbados
Got News to Share?
Got News to Share? globe Explore more publications!

Health Press Barbados: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Press Barbados.

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

Press releases published on May 22, 2026

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
May 22, 2026

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Indeterminate GlobeNewswire
Cartigenix HP® Backed by Three Human Studies as Clinicians Seek Evidence-Based Joint Health Options
May 22, 2026

Cartigenix HP® Backed by Three Human Studies as Clinicians Seek Evidence-Based Joint Health Options

Indeterminate GlobeNewswire
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
May 22, 2026

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

Indeterminate GlobeNewswire
Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi
May 22, 2026

Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi

Indeterminate GlobeNewswire
BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor
May 22, 2026

BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor

Indeterminate GlobeNewswire
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
May 22, 2026

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases

Indeterminate GlobeNewswire
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
May 22, 2026

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

Indeterminate GlobeNewswire
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
May 22, 2026

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

Indeterminate GlobeNewswire
BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung
May 22, 2026

BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung

Indeterminate GlobeNewswire
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
May 22, 2026

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

Indeterminate GlobeNewswire
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
May 22, 2026

China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis

Indeterminate GlobeNewswire
STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026
May 22, 2026

STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026

Indeterminate GlobeNewswire
Hanmi Pharmaceutical se asocia con Organon para exportar terapias combinadas al Sudeste Asiático
May 22, 2026

Hanmi Pharmaceutical se asocia con Organon para exportar terapias combinadas al Sudeste Asiático

Indeterminate GlobeNewswire
Hanmi Pharmaceutical Faz Parceria com a Organon para Exportação de Terapias de Combinação para o Sudeste Asiático
May 22, 2026

Hanmi Pharmaceutical Faz Parceria com a Organon para Exportação de Terapias de Combinação para o Sudeste Asiático

Indeterminate GlobeNewswire
ANGEL Introduces X2 Water Filter System with Advanced Tankless 7-Stage Filtration and 99% PFAS Reduction
May 22, 2026

ANGEL Introduces X2 Water Filter System with Advanced Tankless 7-Stage Filtration and 99% PFAS Reduction

Indeterminate GlobeNewswire
OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire en rechute
May 22, 2026

OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire en rechute

Indeterminate GlobeNewswire
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
May 22, 2026

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer

Indeterminate GlobeNewswire
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
May 22, 2026

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

Indeterminate GlobeNewswire
Medline Inc. announces pricing of upsized secondary offering of Class A common stock
May 22, 2026

Medline Inc. announces pricing of upsized secondary offering of Class A common stock

Indeterminate GlobeNewswire
FemiCore Claims Evaluated: Investigating the Ingredients for Bladder Support - Femi Core Consumer Complaints Exposed
May 22, 2026

FemiCore Claims Evaluated: Investigating the Ingredients for Bladder Support - Femi Core Consumer Complaints Exposed

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
LinkedIn Facebook

Sign up for:

Health Press Barbados

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.